Wells Fargo's chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound) will eventually match statins at roughly 90 million prescriptions, calling the trend “here to stay” because it's prescribed, not faddish.